Poliovirus Vaccine (Inactivated)
- Atc Codes:J07BF
Table of contents
- Brand Names
- Drug Combinations
- Pharmacologic Category
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Dosage
- Special Considerations
Brand Names
Europe
Austria: Polio Salk; Belgium: Imovax Polio; Bulgaria: Imovax Polio, Poliorix; Czech Republic: Imovax Polio, Veropol; Denmark: Poliovaccine; Estonia: Imovax Polio, Poliorix; Finland: Imovax Polio; France: Imovax Polio; Germany: Imovax Polio, IPV Merieux, IPV-Virelon; Greece: Imovax Polio; Ireland: Poliomyelitis Vaccine (Inactivated); Italy: Imovax Polio; Lithuania: Imovax Polio; Poland: Imovax Polio, Inaktywowana; Portugal: Imovax Polio, Poliovaccine; Romania: Imovax Polio, Opvero, Polio Sabin, Poliorix; Slovakia: Imovax Polio; Spain: Vacuna contra la Poliomielitis Inactivada: Sweden: Vaccin mot Polio, VeroPol.
North America
Canada: Imovax Polio, Inactivated Poliomyelitis Vaccine.
Latin America
Argentina: Imovax Polio, Opvero.
Drug combinations
Poliovirus (Type 1, 2, and 3), Diphtheria Toxoid, and Tetanus Toxoid
Poliovirus type 1 (Mahoney), Poliovirus type 2 (MEF 1), and Poliovirus type 3 (Saukett), Bordetella pertussis, Diphtheria Toxoid, Haemophilus influenza b Conjugate Vaccine, Hepatitis B surface Antigen (HbsAg), Pertactin, and Tetanus Toxoid
Chemistry
Pharmacologic Category
Serums, Toxoids, and Vaccines; Vaccines.(ATC-Code: J07BF).
Mechanism of action
Therapeutic use
Active immunization against poliomyelitis caused by poliovirus types 1, 2 and 3.
Pregnancy and lactiation implications
Animal reproduction studies not conducted. Vaccine may be administered to pregnant women at increased risk for infection and requiring immediate protection against polio. Excretion into breast milk unknown (use caution).
Unlabeled use
Contraindications
Hypersensitivity to any component of vaccine.
Warnings and precautions
Anaphylactoid and/or hypersensitivity might occur. Deferral of administration in moderate or severe acute illness should be considered (with or without fever). May be administered to patients with mild acute illness (with or without fever). Patients with prior clinical poliomyelitis or incomplete immunization with oral poliovirus vaccine may receive inactivated poliovirus vaccine. Immune response may be decreased in patients receiving immune globulin. Use with caution in severely immunocompromised patients. Patients with HIV infection, severe combined immunodeficiency, hypogammaglobulinemia, agammaglobulinemia, or altered immunity (due to corticosteroids, alkylating agents, antimetabolites or radiation) may receive inactivated poliovirus vaccine. Products may contain 2-phenoxyethanol, calf serum protein, formaldehyde, neomycin, polymyxin B, or streptomycin. Packaging may contain natural latex rubber.